[GUEST ACCESS MODE: Data is scrambled or limited to provide examples. Make requests using your API key to unlock full data. Check https://lunarcrush.ai/auth for authentication information.] #  @DraMartinezLago Nieves Martinez Lago MD PhD Nieves Martinez Lago MD PhD posts on X about combo, matterhorn, cest, soc the most. They currently have XXXXX followers and XX posts still getting attention that total XXXXX engagements in the last XX hours. ### Engagements: XXXXX [#](/creator/twitter::1053897615295856640/interactions)  - X Week XXXXXX +300% - X Month XXXXXX +87% - X Months XXXXXX +447% - X Year XXXXXX +503,095% ### Mentions: XX [#](/creator/twitter::1053897615295856640/posts_active)  - X Week XX +263% - X Month XX +91% - X Months XX +986% - X Year XX +8,200% ### Followers: XXXXX [#](/creator/twitter::1053897615295856640/followers)  - X Week XXXXX +2.10% - X Month XXXXX +6.50% - X Months XXXXX +21% - X Year XXXXX +43% ### CreatorRank: XXXXXXX [#](/creator/twitter::1053897615295856640/influencer_rank)  ### Social Influence [#](/creator/twitter::1053897615295856640/influence) --- **Social category influence** [nba](/list/nba) #806 [currencies](/list/currencies) [travel destinations](/list/travel-destinations) [cryptocurrencies](/list/cryptocurrencies) **Social topic influence** [combo](/topic/combo), [matterhorn](/topic/matterhorn) #92, [cest](/topic/cest), [soc](/topic/soc), [signals](/topic/signals), [dcr](/topic/dcr), [nets](/topic/nets) #75, [events](/topic/events), [accuracy](/topic/accuracy), [linked](/topic/linked) ### Top Social Posts [#](/creator/twitter::1053897615295856640/posts) --- Top posts by engagements in the last XX hours "🔬 Hidden spark: From cold to hot in BRAF CRC (editorial) 🔗 📖 Refers to original: 🧬 ENC + CET + NIVO in MSS BRAFV600E mCRC 💊 ORR XX% DCR XX% DOR X mo 📊 MAPK + anti-PD-1 combo turns cold tumors hot #DraMartinezLago #CRC" [X Link](https://x.com/DraMartinezLago/status/1976316660903739738) [@DraMartinezLago](/creator/x/DraMartinezLago) 2025-10-09T15:59Z 2403 followers, 2348 engagements "📣 Dont miss #ESMO25 Proffered Session Upper GI (14:00 CEST) X MATTERHORN: Durva+FLOT (resectable GC/GEJ) X SKYSCRAPER-07: Tira+Atezo (post-dCRT ESCC) X LEAP-014: Len+Pembro+CT (1L mESCC) X INTEGRATE IIb: Rego+Nivo (refractory GC/GEJ) X KN026: Anbenitamab+CT (HER2+) @myESMO" [X Link](https://x.com/DraMartinezLago/status/1979109743902834908) [@DraMartinezLago](/creator/x/DraMartinezLago) 2025-10-17T08:58Z 2417 followers, 2297 engagements "#ESMO25 #UpperGI Phase III MATTERHORN: Durvalumab + FLOT vs Placebo + FLOT in resectable G/GEJ cancer (n=948). 🔹 HR XXXX (95% CI 0.630.96); p=0.021 🔹 24-mo OS XXXX% vs XXXX% 36-mo XXXX% vs XXXX% ➡ New SOC for localized G/GEJ cancer" [X Link](https://x.com/DraMartinezLago/status/1979159124538523855) [@DraMartinezLago](/creator/x/DraMartinezLago) 2025-10-17T12:14Z 2417 followers, XXX engagements "🔹 #ESMO25 #Sarcoma Phase III MANEUVER: pimicotinib in TGCT (n=63) 🧩 ORR (BIRC RECIST v1.1): XXXX% (95% CI 63.886.0) 🧩 ORR (TVS): XXXX% (95% CI 62.184.7) Median DOR NR 💪 Sustained tumor response better function pain relief ⚕ Well tolerated few discontinuations" [X Link](https://x.com/DraMartinezLago/status/1979197490923450821) [@DraMartinezLago](/creator/x/DraMartinezLago) 2025-10-17T14:47Z 2417 followers, XXX engagements "#ESMO25 #NETs LITESPARK-015 Belzutifan (HIF-2 inhibitor) in advanced PPGL 🧩 ORR XX% DCR XX% mPFS XX mo mOS NR 🩸 XX% in antihypertensive medication X mo ⚕ Grade XX TRAEs XX% (mostly anemia hypoxia) no grade X 💡 Durable responses with manageable safety ✅ @OncoAlert @myESMO" [X Link](https://x.com/DraMartinezLago/status/1979467628604182583) [@DraMartinezLago](/creator/x/DraMartinezLago) 2025-10-18T08:40Z 2424 followers, 1133 engagements "#ESMO25 #NETs PbVMT--NET (Phase I/IIa NCT05636618) 📈 PR in 4/7 pts (Cohort X XXX MBq) 💊 No G4 AEs no renal toxicity no dysphagia ✅ Well-tolerated next-gen TAT with early efficacy signals 🔬 Further clinical development warranted @myESMO @OncoAlert" [X Link](https://x.com/DraMartinezLago/status/1980172612602134736) [@DraMartinezLago](/creator/x/DraMartinezLago) 2025-10-20T07:21Z 2424 followers, 1194 engagements "#ESMO25 #NETs Belzutifan (HIF-2 inhibitor LITESPARK-015 Phase II) in advanced panNETs 📊 ORR XX% DCR XX% mPFS XXX mo 💊 Anemia (73%) most frequent AE Gr3 XX% ✅ Modest activity with manageable safety profile; further investigation warranted @myESMO @OncoAlert" [X Link](https://x.com/DraMartinezLago/status/1980181548835201063) [@DraMartinezLago](/creator/x/DraMartinezLago) 2025-10-20T07:57Z 2424 followers, 1243 engagements "#ESMO25 #NETs ASPEN: AS vs surgery in X cm NF-PanNETs 🧩 XX% on AS 🧩 5-yr growth XXXX% Liver mets XXX% ⚕ XX% severe post-op issues no deaths 💡 AS and surgery OS similar AS safe for most X cm NF-PanNETs ✅ @myESMO @OncoAlert" [X Link](https://x.com/DraMartinezLago/status/1979464455541899364) [@DraMartinezLago](/creator/x/DraMartinezLago) 2025-10-18T08:27Z 2424 followers, XXX engagements "📢 #ESMO25 #NETs XT-XTR008-3-01 Lu (XTR008) vs hd Octreotide LAR in G12 GEP-NETs 🧩 mPFS XXXX vs XXX mo HR XXXX (p 0.0001) 🧩 ORR XX% vs X% DCR XX% vs XX% ⚕ Manageable safety MDS X% no AML/deaths 💡 XTR008 significantly improved PFS ORR & QoL vs LAR ✅ @myESMO @OncoAlert" [X Link](https://x.com/DraMartinezLago/status/1979479235925356670) [@DraMartinezLago](/creator/x/DraMartinezLago) 2025-10-18T09:26Z 2423 followers, XXX engagements "📢 #ESMO25 #NETs Dabra + trame (Ph III) in RAI-refractory BRAF V600Emt DTC 🧩 mPFS XXXX vs XXX mo HR 0.38; p0.001 🧩 ORR XX% vs X% ⚕ Gr X AEs: pyrexia (6%) anemia (5%) pneumonia (6%) ✅ Benefit across subgroups 💡 New tx for BRAF V600E-mutant DTC @myESMO @OncoAlert" [X Link](https://x.com/DraMartinezLago/status/1979471097520370054) [@DraMartinezLago](/creator/x/DraMartinezLago) 2025-10-18T08:54Z 2424 followers, 1167 engagements "📢 #ESMO25 #NETs COMPETE trial: Lu-edotreotide vs everolimus in G12 GEP-NETs 🧩 mPFS XXXX vs XXXX mo HR XXXX (95% CI 0.480.95); p=0.022 🧩 ORR XX% vs X% (p0.0001) ⚕ Drug-related discontinuations: X% vs XX% 💡 Lu-edotreotide outperforms everolimus safer ✅ @myESMO @OncoAlert" [X Link](https://x.com/DraMartinezLago/status/1979477047199011166) [@DraMartinezLago](/creator/x/DraMartinezLago) 2025-10-18T09:17Z 2424 followers, 1753 engagements "🚨 #ESMO25 #LowerGI 📍 Dont miss Proffered Paper 1: Lower GI 🕓 14:4516:15 💥 Highlights: PEGASUS ctDNA-guided therapy stage IIIII CRC FOxTROT & NICHE-2 neoadjuvant in dMMR colon cancer CITRIC & PARERE ctDNA-driven anti-EGFR in mCRC @myESMO @OncoAlert" [X Link](https://x.com/DraMartinezLago/status/1979479542839321004) [@DraMartinezLago](/creator/x/DraMartinezLago) 2025-10-18T09:27Z 2424 followers, XXX engagements "🚨 Dont miss #ESMO25 #LowerGI 📍 Mini Oral Session 🕓 14:4516:15 X cfDNA blood test for early CRC detection X INTERCEPT ctDNA clearance & outcomes X DESTINY-CRC02 T-DXd in HER2 mCRC (final) X OPTIPRIME Stop-and-go PAN + FOLFOX X TriComB FTD/TPI + Cape + Bev upfront X DeFianCe DKN-01 + Bev + chemo (MSS CRC) X ABBV-400 + Bev (phase I combo) @myESMO @OncoAlert" [X Link](https://x.com/DraMartinezLago/status/1979844012837077454) [@DraMartinezLago](/creator/x/DraMartinezLago) 2025-10-19T09:36Z 2424 followers, XXX engagements "🧬 #ESMO25 #Sarcoma Legubicin vs DOXO in STS (Phase II/III) 📊 mPFS XXXX vs XXX mo HR XXXX (p0.0001) OS HR 0.49; ORR XXXX% vs XXXX% 💗 G3 cardiotoxicity XXX% vs XXXX% G3 hematologic XXXX% vs XXXX% 💥 Potential new 1L standard for advanced STS @myESMO @OncoAlert" [X Link](https://x.com/DraMartinezLago/status/1979921346113966440) [@DraMartinezLago](/creator/x/DraMartinezLago) 2025-10-19T14:43Z 2424 followers, 1070 engagements "🚨 Dont miss #ESMO25 #NETs Mini Oral Session 🕣 08:3010:00 X ZG006 (Phase II): Trispecific T-cell engager (DLL3/DLL3/CD3) in refractory NEC early efficacy. X ZG005 + EP (Phase II): 1L NEC combo showing enhanced activity vs chemo alone. X Triapine + Lu-DOTATATE (Phase I): Synergistic DNA damage + PRRT in well-diff GEP-NETs. X PbVMT--NET & ALPHAMEDIX-02: Targeted alpha therapies with durable responses in SSTR2 NETs. X NUTRIGETNE (GETNE-S2109): Predictive model for malnutrition/sarcopenia in GEP-NENs. X Belzutifan (LITESPARK-015): Promising activity in advanced panNETs. X Organoid models:" [X Link](https://x.com/DraMartinezLago/status/1979938947896586361) [@DraMartinezLago](/creator/x/DraMartinezLago) 2025-10-19T15:53Z 2424 followers, XXX engagements "#ESMO25 #NETs 🧬 Alveltamig (ZG006 Ph II) Trispecific T-cell engager (DLL3/CD3) in refractory NEC 📊 ORR XXXX% (10 mg) vs XXXX% (30 mg) DCR XXXX% vs XXXX% 🎯 DLL3 50%: ORR XXXX% DCR XXXX% 💊 Gr X TRAEs XX% (mostly CRS G1-2) 💥 Supports further dev in DLL3-high NEC @myESMO @OncoAlert" [X Link](https://x.com/DraMartinezLago/status/1980161714680140026) [@DraMartinezLago](/creator/x/DraMartinezLago) 2025-10-20T06:38Z 2424 followers, XXX engagements "#ESMO25 #NETs 🧬 Phase I/II ZG005 (anti-PD-1/TIGIT) + EP in untreated NEC 📊 ORR: XX% (20 mg/kg) vs XX% (10 mg/kg) vs XX% (EP alone) DCR: XXX% 💊 Gr3 TRAEs: XX% (10 mg/kg) XX% (20 mg/kg) XX% (EP); mostly hematologic ✅ Promising efficacy manageable safety. @myESMO @OncoAlert" [X Link](https://x.com/DraMartinezLago/status/1980164427128127840) [@DraMartinezLago](/creator/x/DraMartinezLago) 2025-10-20T06:49Z 2424 followers, XXX engagements "#ESMO25 #NETs 🧬 Phase I NCI trial: Triapine + Lu-DOTATATE in progressive GEP-NETs 📊 ORR XX% (6/28 PR) XX% SD Median PFS NR 💊 AEs: anemia (87%) lymphopenia (87%) thrombocytopenia (71%) mostly transient ✅ DL2 (150 mg) RP2D Phase II (ETCTN 10558)" [X Link](https://x.com/DraMartinezLago/status/1980168940367278428) [@DraMartinezLago](/creator/x/DraMartinezLago) 2025-10-20T07:07Z 2424 followers, XXX engagements "#ESMO25 #NETs 🧬 Phase I NCI trial: Triapine + Lu-DOTATATE in progressive GEP-NETs 📊 ORR XX% (6/28 PR) XX% SD Median PFS NR 💊 AEs: anemia (87%) lymphopenia (87%) thrombocytopenia (71%) mostly transient ✅ DL2 (150 mg) RP2D Phase II (ETCTN 10558) @myESMO @OncoAlert" [X Link](https://x.com/DraMartinezLago/status/1980169053898420265) [@DraMartinezLago](/creator/x/DraMartinezLago) 2025-10-20T07:07Z 2424 followers, XXX engagements "#ESMO25 #NETs Phase II ALPHAMEDIX-02 Pb-DOTAMTATE in RLT-nave adv GEP-NETs 📊 ORR XX% DCR XX% DoR 24m (72%) 36m PFS XX% OS XX% 💊 Mostly G12 AEs; rare dysphagia/renal events; no MDS/AML ✅ Durable efficacy + safe profile confirm -therapy as promising NET option @myESMO @OncoAlert" [X Link](https://x.com/DraMartinezLago/status/1980173327663526344) [@DraMartinezLago](/creator/x/DraMartinezLago) 2025-10-20T07:24Z 2424 followers, XXX engagements "#ESMO25 #NETs @drdelolmo_mbel presents NUTRIGETNE (GETNE-S2109) study 💪 📊 Cross-sectional study in adv. GEP-NENs 🔎 LASSO models for malnutrition (GLIM) & sarcopenia (EWGSOP) 🎯 Accuracy: XXXX% (malnutrition) XXXX% (sarcopenia) ✅ NUTRIGETNE Score: accessible rapid cost-effective nutritional risk screening tool @myESMO @OncoAlert" [X Link](https://x.com/DraMartinezLago/status/1980179934346682609) [@DraMartinezLago](/creator/x/DraMartinezLago) 2025-10-20T07:51Z 2424 followers, XXX engagements "#ESMO25 #UpperGI IMMUNOBIL (Phase II) Durvalumab + tremelimumab (STRIDE) in pretreated BTC 📊 6-mo OS XX% mOS XXX mo ORR XX% DCR XX% 💊 Gr3 TRAE XX% PD-L1 X linked to better OS (12.8 vs XXX mo) ⚠ Primary endpoint narrowly missed but activity seen in subsets @OncoAlert" [X Link](https://x.com/DraMartinezLago/status/1980279555848859849) [@DraMartinezLago](/creator/x/DraMartinezLago) 2025-10-20T14:26Z 2424 followers, XXX engagements "#ESMO25 #UpperGI VIRAGE (Phase IIb) VCN-01 + gem/nab-paclitaxel vs GA alone in mPDAC 📈 mOS XXXX vs XXX mo (HR 0.57; p=0.055) mPFS XXX vs XXX mo (p=0.011) 💊 Well tolerated; transient flu-like & liver AEs ✅ Improved OS PFS & DoR; meets primary endpoint @myESMO @OncoAlert" [X Link](https://x.com/DraMartinezLago/status/1980281229795885080) [@DraMartinezLago](/creator/x/DraMartinezLago) 2025-10-20T14:33Z 2424 followers, XXX engagements
[GUEST ACCESS MODE: Data is scrambled or limited to provide examples. Make requests using your API key to unlock full data. Check https://lunarcrush.ai/auth for authentication information.]
Nieves Martinez Lago MD PhD posts on X about combo, matterhorn, cest, soc the most. They currently have XXXXX followers and XX posts still getting attention that total XXXXX engagements in the last XX hours.
Social category influence nba #806 currencies travel destinations cryptocurrencies
Social topic influence combo, matterhorn #92, cest, soc, signals, dcr, nets #75, events, accuracy, linked
Top posts by engagements in the last XX hours
"🔬 Hidden spark: From cold to hot in BRAF CRC (editorial) 🔗 📖 Refers to original: 🧬 ENC + CET + NIVO in MSS BRAFV600E mCRC 💊 ORR XX% DCR XX% DOR X mo 📊 MAPK + anti-PD-1 combo turns cold tumors hot #DraMartinezLago #CRC"
X Link @DraMartinezLago 2025-10-09T15:59Z 2403 followers, 2348 engagements
"📣 Dont miss #ESMO25 Proffered Session Upper GI (14:00 CEST) X MATTERHORN: Durva+FLOT (resectable GC/GEJ) X SKYSCRAPER-07: Tira+Atezo (post-dCRT ESCC) X LEAP-014: Len+Pembro+CT (1L mESCC) X INTEGRATE IIb: Rego+Nivo (refractory GC/GEJ) X KN026: Anbenitamab+CT (HER2+) @myESMO"
X Link @DraMartinezLago 2025-10-17T08:58Z 2417 followers, 2297 engagements
"#ESMO25 #UpperGI Phase III MATTERHORN: Durvalumab + FLOT vs Placebo + FLOT in resectable G/GEJ cancer (n=948). 🔹 HR XXXX (95% CI 0.630.96); p=0.021 🔹 24-mo OS XXXX% vs XXXX% 36-mo XXXX% vs XXXX% ➡ New SOC for localized G/GEJ cancer"
X Link @DraMartinezLago 2025-10-17T12:14Z 2417 followers, XXX engagements
"🔹 #ESMO25 #Sarcoma Phase III MANEUVER: pimicotinib in TGCT (n=63) 🧩 ORR (BIRC RECIST v1.1): XXXX% (95% CI 63.886.0) 🧩 ORR (TVS): XXXX% (95% CI 62.184.7) Median DOR NR 💪 Sustained tumor response better function pain relief ⚕ Well tolerated few discontinuations"
X Link @DraMartinezLago 2025-10-17T14:47Z 2417 followers, XXX engagements
"#ESMO25 #NETs LITESPARK-015 Belzutifan (HIF-2 inhibitor) in advanced PPGL 🧩 ORR XX% DCR XX% mPFS XX mo mOS NR 🩸 XX% in antihypertensive medication X mo ⚕ Grade XX TRAEs XX% (mostly anemia hypoxia) no grade X 💡 Durable responses with manageable safety ✅ @OncoAlert @myESMO"
X Link @DraMartinezLago 2025-10-18T08:40Z 2424 followers, 1133 engagements
"#ESMO25 #NETs PbVMT--NET (Phase I/IIa NCT05636618) 📈 PR in 4/7 pts (Cohort X XXX MBq) 💊 No G4 AEs no renal toxicity no dysphagia ✅ Well-tolerated next-gen TAT with early efficacy signals 🔬 Further clinical development warranted @myESMO @OncoAlert"
X Link @DraMartinezLago 2025-10-20T07:21Z 2424 followers, 1194 engagements
"#ESMO25 #NETs Belzutifan (HIF-2 inhibitor LITESPARK-015 Phase II) in advanced panNETs 📊 ORR XX% DCR XX% mPFS XXX mo 💊 Anemia (73%) most frequent AE Gr3 XX% ✅ Modest activity with manageable safety profile; further investigation warranted @myESMO @OncoAlert"
X Link @DraMartinezLago 2025-10-20T07:57Z 2424 followers, 1243 engagements
"#ESMO25 #NETs ASPEN: AS vs surgery in X cm NF-PanNETs 🧩 XX% on AS 🧩 5-yr growth XXXX% Liver mets XXX% ⚕ XX% severe post-op issues no deaths 💡 AS and surgery OS similar AS safe for most X cm NF-PanNETs ✅ @myESMO @OncoAlert"
X Link @DraMartinezLago 2025-10-18T08:27Z 2424 followers, XXX engagements
"📢 #ESMO25 #NETs XT-XTR008-3-01 Lu (XTR008) vs hd Octreotide LAR in G12 GEP-NETs 🧩 mPFS XXXX vs XXX mo HR XXXX (p 0.0001) 🧩 ORR XX% vs X% DCR XX% vs XX% ⚕ Manageable safety MDS X% no AML/deaths 💡 XTR008 significantly improved PFS ORR & QoL vs LAR ✅ @myESMO @OncoAlert"
X Link @DraMartinezLago 2025-10-18T09:26Z 2423 followers, XXX engagements
"📢 #ESMO25 #NETs Dabra + trame (Ph III) in RAI-refractory BRAF V600Emt DTC 🧩 mPFS XXXX vs XXX mo HR 0.38; p0.001 🧩 ORR XX% vs X% ⚕ Gr X AEs: pyrexia (6%) anemia (5%) pneumonia (6%) ✅ Benefit across subgroups 💡 New tx for BRAF V600E-mutant DTC @myESMO @OncoAlert"
X Link @DraMartinezLago 2025-10-18T08:54Z 2424 followers, 1167 engagements
"📢 #ESMO25 #NETs COMPETE trial: Lu-edotreotide vs everolimus in G12 GEP-NETs 🧩 mPFS XXXX vs XXXX mo HR XXXX (95% CI 0.480.95); p=0.022 🧩 ORR XX% vs X% (p0.0001) ⚕ Drug-related discontinuations: X% vs XX% 💡 Lu-edotreotide outperforms everolimus safer ✅ @myESMO @OncoAlert"
X Link @DraMartinezLago 2025-10-18T09:17Z 2424 followers, 1753 engagements
"🚨 #ESMO25 #LowerGI 📍 Dont miss Proffered Paper 1: Lower GI 🕓 14:4516:15 💥 Highlights: PEGASUS ctDNA-guided therapy stage IIIII CRC FOxTROT & NICHE-2 neoadjuvant in dMMR colon cancer CITRIC & PARERE ctDNA-driven anti-EGFR in mCRC @myESMO @OncoAlert"
X Link @DraMartinezLago 2025-10-18T09:27Z 2424 followers, XXX engagements
"🚨 Dont miss #ESMO25 #LowerGI 📍 Mini Oral Session 🕓 14:4516:15 X cfDNA blood test for early CRC detection X INTERCEPT ctDNA clearance & outcomes X DESTINY-CRC02 T-DXd in HER2 mCRC (final) X OPTIPRIME Stop-and-go PAN + FOLFOX X TriComB FTD/TPI + Cape + Bev upfront X DeFianCe DKN-01 + Bev + chemo (MSS CRC) X ABBV-400 + Bev (phase I combo) @myESMO @OncoAlert"
X Link @DraMartinezLago 2025-10-19T09:36Z 2424 followers, XXX engagements
"🧬 #ESMO25 #Sarcoma Legubicin vs DOXO in STS (Phase II/III) 📊 mPFS XXXX vs XXX mo HR XXXX (p0.0001) OS HR 0.49; ORR XXXX% vs XXXX% 💗 G3 cardiotoxicity XXX% vs XXXX% G3 hematologic XXXX% vs XXXX% 💥 Potential new 1L standard for advanced STS @myESMO @OncoAlert"
X Link @DraMartinezLago 2025-10-19T14:43Z 2424 followers, 1070 engagements
"🚨 Dont miss #ESMO25 #NETs Mini Oral Session 🕣 08:3010:00 X ZG006 (Phase II): Trispecific T-cell engager (DLL3/DLL3/CD3) in refractory NEC early efficacy. X ZG005 + EP (Phase II): 1L NEC combo showing enhanced activity vs chemo alone. X Triapine + Lu-DOTATATE (Phase I): Synergistic DNA damage + PRRT in well-diff GEP-NETs. X PbVMT--NET & ALPHAMEDIX-02: Targeted alpha therapies with durable responses in SSTR2 NETs. X NUTRIGETNE (GETNE-S2109): Predictive model for malnutrition/sarcopenia in GEP-NENs. X Belzutifan (LITESPARK-015): Promising activity in advanced panNETs. X Organoid models:"
X Link @DraMartinezLago 2025-10-19T15:53Z 2424 followers, XXX engagements
"#ESMO25 #NETs 🧬 Alveltamig (ZG006 Ph II) Trispecific T-cell engager (DLL3/CD3) in refractory NEC 📊 ORR XXXX% (10 mg) vs XXXX% (30 mg) DCR XXXX% vs XXXX% 🎯 DLL3 50%: ORR XXXX% DCR XXXX% 💊 Gr X TRAEs XX% (mostly CRS G1-2) 💥 Supports further dev in DLL3-high NEC @myESMO @OncoAlert"
X Link @DraMartinezLago 2025-10-20T06:38Z 2424 followers, XXX engagements
"#ESMO25 #NETs 🧬 Phase I/II ZG005 (anti-PD-1/TIGIT) + EP in untreated NEC 📊 ORR: XX% (20 mg/kg) vs XX% (10 mg/kg) vs XX% (EP alone) DCR: XXX% 💊 Gr3 TRAEs: XX% (10 mg/kg) XX% (20 mg/kg) XX% (EP); mostly hematologic ✅ Promising efficacy manageable safety. @myESMO @OncoAlert"
X Link @DraMartinezLago 2025-10-20T06:49Z 2424 followers, XXX engagements
"#ESMO25 #NETs 🧬 Phase I NCI trial: Triapine + Lu-DOTATATE in progressive GEP-NETs 📊 ORR XX% (6/28 PR) XX% SD Median PFS NR 💊 AEs: anemia (87%) lymphopenia (87%) thrombocytopenia (71%) mostly transient ✅ DL2 (150 mg) RP2D Phase II (ETCTN 10558)"
X Link @DraMartinezLago 2025-10-20T07:07Z 2424 followers, XXX engagements
"#ESMO25 #NETs 🧬 Phase I NCI trial: Triapine + Lu-DOTATATE in progressive GEP-NETs 📊 ORR XX% (6/28 PR) XX% SD Median PFS NR 💊 AEs: anemia (87%) lymphopenia (87%) thrombocytopenia (71%) mostly transient ✅ DL2 (150 mg) RP2D Phase II (ETCTN 10558) @myESMO @OncoAlert"
X Link @DraMartinezLago 2025-10-20T07:07Z 2424 followers, XXX engagements
"#ESMO25 #NETs Phase II ALPHAMEDIX-02 Pb-DOTAMTATE in RLT-nave adv GEP-NETs 📊 ORR XX% DCR XX% DoR 24m (72%) 36m PFS XX% OS XX% 💊 Mostly G12 AEs; rare dysphagia/renal events; no MDS/AML ✅ Durable efficacy + safe profile confirm -therapy as promising NET option @myESMO @OncoAlert"
X Link @DraMartinezLago 2025-10-20T07:24Z 2424 followers, XXX engagements
"#ESMO25 #NETs @drdelolmo_mbel presents NUTRIGETNE (GETNE-S2109) study 💪 📊 Cross-sectional study in adv. GEP-NENs 🔎 LASSO models for malnutrition (GLIM) & sarcopenia (EWGSOP) 🎯 Accuracy: XXXX% (malnutrition) XXXX% (sarcopenia) ✅ NUTRIGETNE Score: accessible rapid cost-effective nutritional risk screening tool @myESMO @OncoAlert"
X Link @DraMartinezLago 2025-10-20T07:51Z 2424 followers, XXX engagements
"#ESMO25 #UpperGI IMMUNOBIL (Phase II) Durvalumab + tremelimumab (STRIDE) in pretreated BTC 📊 6-mo OS XX% mOS XXX mo ORR XX% DCR XX% 💊 Gr3 TRAE XX% PD-L1 X linked to better OS (12.8 vs XXX mo) ⚠ Primary endpoint narrowly missed but activity seen in subsets @OncoAlert"
X Link @DraMartinezLago 2025-10-20T14:26Z 2424 followers, XXX engagements
"#ESMO25 #UpperGI VIRAGE (Phase IIb) VCN-01 + gem/nab-paclitaxel vs GA alone in mPDAC 📈 mOS XXXX vs XXX mo (HR 0.57; p=0.055) mPFS XXX vs XXX mo (p=0.011) 💊 Well tolerated; transient flu-like & liver AEs ✅ Improved OS PFS & DoR; meets primary endpoint @myESMO @OncoAlert"
X Link @DraMartinezLago 2025-10-20T14:33Z 2424 followers, XXX engagements
/creator/x::DraMartinezLago